Efficacy and Safety of Catheter abLation in patiEnts With seVere Atrial Functional Mitral regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

December 1, 2026

Conditions
Atrial Fibrillation (AF)Catheter AblationAtrial Functional Mitral Regurgitation
Interventions
PROCEDURE

Catheter ablation plus medication

All patients will receive atrial fibrillation catheter ablation. They also should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.

DRUG

Medication

Patients will receive guideline-directed medical therapy, anticoagulation, and rate control according to the guidelines for the management of AF and heart failure.

PROCEDURE

(ELEVATE-AF X) experimental group

Subsequent ablations may be considered for patients with recurrence,and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.

PROCEDURE

(ELEVATE-AF X) control group

All patients could receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.

Trial Locations (2)

100029

Beijing Anzhen Hospital, Capital Medical University, Beijing

310009

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Beijing Anzhen Hospital

OTHER

NCT06883864 - Efficacy and Safety of Catheter abLation in patiEnts With seVere Atrial Functional Mitral regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial | Biotech Hunter | Biotech Hunter